MT3 melatonin binding site, MT1 and MT2 melatonin receptors are present in oocyte, but only MT1 is present in bovine blastocyst produced in vitro

Sampaio, Rafael Vilar; Conceição, Dhúllia Stefanne B; Miranda, M. S.; Sampaio, Lucia de Fatima Sobral; Ohashi, Otávio Mitio

doi:10.1186/1477-7827-10-103

Cited by 54 publications

(47 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Sampaio et al. reported that both MT1 and MT2 are present in oocyte; however, only MT1 is present in bovine blastocyst produced in vitro. Our current study revealed that both MT1 and MT2 genes are expressed in bovine embryos produced in vitro.…”

Section: Discussionmentioning

confidence: 99%

Beneficial effects of melatonin on in vitro bovine embryonic development are mediated by melatonin receptor 1

Wang

Tian

Zhang

et al. 2014

Journal of Pineal Research

View full text Add to dashboard Cite

In the current study, a fundamental question, that is, the mechanisms related to the beneficial effects of melatonin on mammalian embryonic development, was addressed. To examine the potential beneficial effects of melatonin on bovine embryonic development, different concentrations of melatonin (10(-11), 10(-9), 10(-7), 10(-5), 10(-3) M) were incubated with fertilized embryos. Melatonin in the range of 10(-11) to 10(-5) M significantly promoted embryonic development both in early culture medium (CR1aa +3 mg/mL BSA) and in later culture medium (CR1aa + 6%FBS). The most effective concentrations applied in the current studies were 10(-9) and 10(-7) M. Using quantitative real-time PCR with immunofluorescence and Western blot assays, the expression of melatonin receptor MT1 and MT2 genes was identified in bovine embryos. Further studies indicate that the beneficial effects of melatonin on bovine embryo development were mediated by the MT1 receptor. This is based on the facts that luzindole, a nonselective MT1 and MT2 antagonist, blocked the effect on melatonin-induced embryo development, while 4-P-PDOT, a selective MT2 antagonist, had little effect. Mechanistic explorations uncovered that melatonin application during bovine embryonic development significantly up-regulated the expression of antioxidative (Gpx4, SOD1, bcl-2) and developmentally important genes (SLC2A1, DNMT1A, and DSC2) while down-regulating expression of pro-apoptotic genes (P53, BAX, and Caspase-3). The results obtained from the current studies provide new information regarding the mechanisms by which melatonin promotes bovine embryonic development under both in vitro and in vivo conditions.

show abstract

Section: Discussionmentioning

confidence: 99%

Beneficial effects of melatonin on in vitro bovine embryonic development are mediated by melatonin receptor 1

Wang

Tian

Zhang

et al. 2014

Journal of Pineal Research

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown the expression of melatonin MT1 receptors in oocytes, cumulus cells and bovine blastocysts [50,51]. Studies on other species have shown the presence of MT1 receptor transcripts in porcine cumulus cells and granulosa cells but not in oocytes [22].…”

Section: Discussionmentioning

confidence: 99%

“…However, in some cells, melatonin causes stimulation of cAMP, and this stimulatory effect is independent of G proteins [53]. Activation of MT1 receptor stimulates phosphoinositide turnover and inhibits the guanylate cyclase enzyme and can induce PKC activation by Ca2+ waves, in parallel with the inhibition of the cAMP pathways [22,50,51]. Cellular signaling of melatonin receptors needs further investigations to understand the melatonin role in preimplantation development.…”

Section: Discussionmentioning

confidence: 99%

Melatonin modulates the expression of BCL-xl and improve the development of vitrified embryos obtained by IVF in mice

Dehghani-Mohammadabadi

Salehi

Farifteh

et al. 2014

J Assist Reprod Genet

View full text Add to dashboard Cite

show abstract

“…Several human and animal studies support the use of melatonin in the treatment of infertility, with beneficial actions being largely attributed to its antioxidant properties. Furthermore, melatonin receptors are found on granulosa cells, oocytes and embryos,49 with intrafollicular melatonin concentrations being significantly higher than those found in serum, again suggesting a physiological role in reproduction 39 50 51. The human studies addressing the use of melatonin in infertility treatment undertaken to date have been small and not placebo-controlled.…”

Section: Rationalementioning

confidence: 98%

A pilot double-blind randomised placebo-controlled dose–response trial assessing the effects of melatonin on infertility treatment (MIART): study protocol

et al. 2014

View full text Add to dashboard Cite

IntroductionHigh levels of oxidative stress can have considerable impact on the outcomes of in vitro fertilisation (IVF). Recent studies have reported that melatonin, a neurohormone secreted from the pineal gland in response to darkness, has significant antioxidative capabilities which may protect against the oxidative stress of infertility treatment on gametes and embryos. Early studies of oral melatonin (3–4 mg/day) in IVF have suggested favourable outcomes. However, most trials were poorly designed and none have addressed the optimum dose of melatonin. We present a proposal for a pilot double-blind randomised placebo-controlled dose–response trial aimed to determine whether oral melatonin supplementation during ovarian stimulation can improve the outcomes of assisted reproductive technology.Methods and analysesWe will recruit 160 infertile women into one of four groups: placebo (n=40); melatonin 2 mg twice per day (n=40); melatonin 4 mg twice per day (n=40) and melatonin 8 mg twice per day (n=40). The primary outcome will be clinical pregnancy rate. Secondary clinical outcomes include oocyte number/quality, embryo number/quality and fertilisation rate. We will also measure serum melatonin and the oxidative stress marker, 8-hydroxy-2′-deoxyguanosine at baseline and after treatment and levels of these in follicular fluid at egg pick-up. We will investigate follicular blood flow with Doppler ultrasound, patient sleepiness scores and pregnancy complications, comparing outcomes between groups. This protocol has been designed in accordance with the SPIRIT 2013 Guidelines.Ethics and disseminationEthical approval has been obtained from Monash Health HREC (Ref: 13402B), Monash University HREC (Ref: CF14/523-2014000181) and Monash Surgical Private Hospital HREC (Ref: 14107). Data analysis, interpretation and conclusions will be presented at national and international conferences and published in peer-reviewed journals.Trial registration numberACTRN12613001317785.

show abstract

MT3 melatonin binding site, MT1 and MT2 melatonin receptors are present in oocyte, but only MT1 is present in bovine blastocyst produced in vitro

Cited by 54 publications

References 42 publications

Beneficial effects of melatonin on in vitro bovine embryonic development are mediated by melatonin receptor 1

Beneficial effects of melatonin on in vitro bovine embryonic development are mediated by melatonin receptor 1

Melatonin modulates the expression of BCL-xl and improve the development of vitrified embryos obtained by IVF in mice

A pilot double-blind randomised placebo-controlled dose–response trial assessing the effects of melatonin on infertility treatment (MIART): study protocol

Contact Info

Product

Resources

About